Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ChronTech Pharma's vaccine acts against liver cells that produce parts of HDV


Thursday, 30 Jan 2014 07:17am EST 

ChronTech Pharma AB:Says the company's therapeutic vaccine against hepatitis D virus (HDV) infection activates the immune response so that it can go into the liver and eliminate those liver cells that produce parts of HDV in the mouse model.Says this is the first proof of concept in vivo showing that the vaccine is able to activate the immune response so that it can recognize and make an antiviral effect on HDV-infected cells.Says the company to develop both a therapeutic vaccine against HDV and a protective vaccine against HDV.